The FDA peptide decision people keep asking about hasn't happened yet. In July an outside expert panel spent two days voting on whether seven peptides — BPC-157, TB-500 and MOTS-c among them — belong on a list of raw ingredients that compounding pharmacies are allowed to start from. Those votes were advice. The agency hasn't turned any of them into a rule, and nothing about how these are prescribed has changed.
If you have a prescription today, you still have it. Here's what the vote actually was, what has happened since, and what would have to happen before anything real changes.
What actually happened in July
The Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 at FDA's campus in Silver Spring, Maryland. It's a standing panel of outside pharmacists, doctors and public members the agency calls together for advice on compounding. FDA's description of the arrangement is blunt: these panels "make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so."
The question in front of them was narrower than the headlines suggested. A compounding pharmacy can't start from any powder it likes: the ingredient has to meet an official quality standard, or already be part of an approved drug, or sit on one specific FDA list. These seven meet neither of the first two, so the list is the only route — and the panel was asked, one substance at a time, whether each belongs on it.
They weren't asked about the peptides in general, either. FDA reviewed each one for a single named use, and that use is what got voted on.
| Peptide | The use FDA reviewed | The panel's vote |
|---|---|---|
| BPC-157 | Ulcerative colitis | 8–6–1, in favour |
| KPV | Wound healing and inflammatory conditions | 8–6–1, in favour |
| TB-500 | Wound healing | 8–6–1, in favour |
| MOTS-c | Obesity and osteoporosis | 7–5–2, in favour |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | 8–5–1, in favour |
| Epitalon | Insomnia | 7–4–1, in favour |
| Emideltide (DSIP) | Opioid withdrawal, chronic insomnia, narcolepsy | 6–7–1, against |
The panel voted twice on each peptide — once on the plain form, once on the acetate salt. On BPC-157 it went against FDA's own reviewers, whose briefing document called the ingredient poorly characterised chemically, the safety information thin and the evidence for treating ulcerative colitis insufficient, and proposed not adding it. The panel disagreed, by two votes.
Where the FDA peptide decision stands right now
As of September 6, 2026, the day this article was written, nothing has been published. Three checks, all of them repeatable.
The Federal Register — the government's daily notice board, where a real rule would appear — carries four documents mentioning peptides since August 1: an NIH patent notice, an FDA guidance on immunotherapy potency, an aviation medical rule and a Medicare payment rule. None of them touches compounding peptides for people.
FDA's page explaining the ingredient list itself still reads "Content current as of: 05/14/2026" — two months before the meeting.
And the meeting's own materials page still ends at the slide decks — no minutes, no summary, no published vote record. The tallies above come from the roll call taken in the public session.
None of that is unusual. FDA has been working through this batch of ingredient nominations since 2015.
What it means if you take one of these
Practically, nothing changed. The list governs which raw ingredients a pharmacy may work from as a general matter. It is not a switch that turns a medicine on or off for one patient. A licensed provider may still prescribe a compounded formulation of any of these, and that decision is between you and your doctor.
Compounding is its own regulated lane rather than a workaround — a pharmacy preparing a medicine for one named patient against one prescription, which is how compounded medications are made.
What hasn't changed either is the gate at the front. Every request goes through a medical intake and a licensed provider who reads it and decides, and not everyone qualifies. Being told no is a normal outcome of that review, not a fault in it.
What a vote against would not mean
The word people reach for is the wrong one. A vote against adding an ingredient to a list is not a removal from the market, and the committee couldn't order one anyway. It advises.
Two more things the votes don't say.
They are use-specific. The BPC-157 vote was about ulcerative colitis, an inflammatory bowel condition. Most people asking about BPC-157 are asking about a joint, a tendon or a gut complaint that isn't ulcerative colitis, and a panel weighing evidence in one condition isn't weighing it in another.
They don't confer approval. Landing on that list would not make any of these an approved drug — it is an ingredient list for pharmacy compounding, a different thing entirely. There is no FDA-approved BPC-157 product, and FDA's own review notes none exists in any country. The same distinction runs through the GLP-1s, where the brand-name products are approved and the compounded version is not FDA-approved.
What the research actually shows
Two reviews published in the last month land in the same place.
A scoping review in the American Journal of Sports Medicine, published online on August 11, 2026, gathered the published work on six compounds — BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu and MK-677 — for muscle, tendon, bone and ligament healing. Roughly two-thirds of it was animal work, mostly in rats. The human studies were "limited to a handful of investigations, most lacking robust controls," and the review concluded that the claimed benefits remain unsubstantiated by current human trials.
A second review, in Current Pain and Headache Reports on August 24, 2026, came at it from pain medicine and reached the sentence that matters most here: because most of these remain unapproved and the human evidence is limited, their use "should be guided by careful clinical judgment and ongoing evaluation of emerging evidence."
That is a description of a doctor. It is also the argument for the prescription route over a vial ordered from a website — a different question from anything the committee voted on, and one that has been measured. In a 2024 study in the Journal of Medical Internet Research, researchers ordered semaglutide from online sellers shipping without a prescription. Three vials arrived; three orders never came. The three that arrived tested between 7.7% and 14.4% pure against the 99% printed on the label, and every one carried detectable endotoxin — bacterial residue that can cause fever. Whether peptides are legal is a separate question with its own answer.
What to watch next
Three things, in order of how much they would actually change.
The next advisory meeting. FDA says it will hold one before the end of February 2027. The agenda is already published and it covers five different substances: cathelicidin LL-37, GHK-Cu, dihexa acetate, melanotan II and pegylated mechano growth factor. None of the seven from July is on it.
A proposed rule. This is the one that counts. Any real change to the list arrives as a proposed rule in the Federal Register with a comment period attached, then a final rule. Until that publishes, nothing has changed on paper.
A bill, at the edge of relevance. On September 1, 2026, Rep. Nancy Mace introduced H.R. 10212, the PEPTIDES for Veterans Act, which would have the Department of Veterans Affairs study peptide therapies for veterans in its care. It went to the Veterans' Affairs Committee the same day. It has been introduced, not passed, and it would not change compounding rules if it were.
Everything else is commentary. The decision people are waiting for will look like a document with a publication date on it, and there isn't one yet.